Sourced by Personalis:
Personalis (PSNL) has the potential for becoming one of the key players in the growing immunotherapy market with an established and budding ability to provide the analytical molecular data for individual patient's cancer and immune response. In my opinion, the current stock price provides an investor a good entry level for ownership of their stock. With the following commentary, I hope to lay out the basis for my enthusiasm for the stock.
Instead of me trying to create in my laymen terms what Personalis is all about, the following is what they